MPN Research Foundation is a patient-founded nonprofit organization dedicated to funding and advancing research aimed at developing new treatments and ultimately a cure for myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and myelofibrosis.
Established in 1999 in Chicago, Illinois, by patients including Robert Rosen, it was the first organization focused exclusively on these rare blood cancers and has grown into the global leader in MPN research acceleration. The foundation has awarded more than $20 million in grants to support innovative, high-risk projects worldwide.
Operating as an independent 501(c)(3) nonprofit, MPN Research Foundation collaborates with patients, caregivers, researchers, clinicians, and the biopharmaceutical industry. Its activities include funding scientific studies, maintaining the MPN Research Consortium Tissue Bank, providing educational resources and advocacy, and facilitating clinical trial access. Research supported spans multiple countries and has contributed to key discoveries, such as the CALR mutation.
The organization emphasizes a patient-centered approach, elevating the patient voice in drug development, and positions itself as a key player in the MPN ecosystem by bridging stakeholders to speed progress toward better outcomes for those affected by these diseases.
Official website: mpnresearchfoundation.org
To provide comprehensive coverage, we aggregate data and news under the name MPNRF, encompassing the following company names, divisions, and related entities:
MPD Foundation and The MPN Research Foundation.
This list encompasses current and former names, alternate names, and key divisions associated with MPNRF, ensuring you can easily find all relevant information under a single, unified profile.
